Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

Hong Kong Exchange publishes share repurchases by listed companies on a daily basis. In our weekly note, we will provide statistics on top repurchases over one week, one month, one quarter and one year periods ended on Oct 29.In the past 7 days, the top 3 companies that repurchased the most shares from the market were China Gas Holdings Limited (384 HK) (HKD 91.4 million worth of buybacks), Hopson Development Holdings Limited (754 HK) (HKD 84.2 million worth of buybacks), Sihuan Pharmaceutical Holdings Group Ltd. (460 HK) (HKD 57.2 million worth of buybacks).

Hong Kong Exchange publishes share repurchases by listed companies on a daily basis. In our weekly note, we will provide statistics on top repurchases over one week, one month, one quarter and one year periods ended on Oct 29.In the past 7 days, the top 3 companies that repurchased the most shares from the market were China Gas Holdings Limited (384 HK) (HKD 91.4 million worth of buybacks), Hopson Development Holdings Limited (754 HK) (HKD 84.2 million worth of buybacks), Sihuan Pharmaceutical Holdings Group Ltd. (460 HK) (HKD 57.2 million worth of buybacks).

Hong Kong Buybacks: China Gas, Hopson, Sihuan

Hong Kong Exchange publishes share repurchases by listed companies on a daily basis. In our weekly note, we will provide statistics on top repurchases over one week, one month, one quarter and one year periods ended on Oct 22.In the past 7 days, the top 3 companies that repurchased the most shares from the market were Xiaomi Corporation (1810 HK) (HKD 147.5 million worth of buybacks), China Gas Holdings Limited (384 HK) (HKD 75.9 million worth of buybacks), Sihuan Pharmaceutical Holdings Group Ltd. (460 HK) (HKD 70.2 million worth of buybacks).

Hong Kong Exchange publishes share repurchases by listed companies on a daily basis. In our weekly note, we will provide statistics on top repurchases over one week, one month, one quarter and one year periods ended on Oct 22.In the past 7 days, the top 3 companies that repurchased the most shares from the market were Xiaomi Corporation (1810 HK) (HKD 147.5 million worth of buybacks), China Gas Holdings Limited (384 HK) (HKD 75.9 million worth of buybacks), Sihuan Pharmaceutical Holdings Group Ltd. (460 HK) (HKD 70.2 million worth of buybacks).

Hong Kong Buybacks: Xiaomi, China Gas, Sihuan

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<a href="https://www.smartkarma.com/entities/sihuan-pharmaceutical-hldgs" target="_blank" data-smartkarma-citation="entities:33:1" rel="noopener">Sihuan Pharmaceutical Hldgs (460 HK)</a>’s share price fell for two consecutive days on Sep.27 and Sep.28, decreasing 11% and 17.98%, respectively. According to public news, recently, Sihuan filed a lawsuit against CBC Group for infringement of trade secrets and such lawsuit has been formally accepted by the Beijing Intellectual Property Court. Meanwhile, there are also concerns on the acquisition of Hugel by CBC Group that may affect Sihuan’s exclusive distribution rights in China for Botulinum Toxin Type A (Letybo) and Hyaluronic Acid. On Sep.30, Sihuan made an announcement to claim that the Company does not expect its exclusive distribution rights will be affected by the Hugel Acquisition. This insight mainly analyzed the potential impact of the acquisition, the business and the outlook of the Company.

Sihuan Pharmaceutical Hldgs (460 HK)’s share price fell for two consecutive days on Sep.27 and Sep.28, decreasing 11% and 17.98%, respectively. According to public news, recently, Sihuan filed a lawsuit against CBC Group for infringement of trade secrets and such lawsuit has been formally accepted by the Beijing Intellectual Property Court. Meanwhile, there are also concerns on the acquisition of Hugel by CBC Group that may affect Sihuan’s exclusive distribution rights in China for Botulinum Toxin Type A (Letybo) and Hyaluronic Acid. On Sep.30, Sihuan made an announcement to claim that the Company does not expect its exclusive distribution rights will be affected by the Hugel Acquisition. This insight mainly analyzed the potential impact of the acquisition, the business and the outlook of the Company.

Sihuan Pharmaceutical (460.HK) - The Dispute with CBC Group, the Business and the Outlook

Since 2021, if you want to ask which sector in the healthcare industry has outstanding performance, the medical beauty sector is definitely the one. Looking at the leading companies in this sector, the market cap and P/E ratio of <a href="https://www.smartkarma.com/entities/bloomage-biotechnology-corporation-a" target="_blank" data-smartkarma-citation="entities:30390:1" rel="noopener">Bloomage Biotechnology Corporation-A (688363 CH)</a> by the end of May 28, 2021 were RMB121 billion and 175, respectively. For <a href="https://www.smartkarma.com/entities/imeik-technology-development-co-ltd" target="_blank" data-smartkarma-citation="entities:32170:1" rel="noopener">Imeik Technology Development (300896 CH)</a>, they were RMB142 billion and 250, respectively. Both were at high end and very expensive. Here is another company, <a href="https://www.smartkarma.com/entities/sihuan-pharmaceutical-hldgs" target="_blank" data-smartkarma-citation="entities:33:1" rel="noopener">Sihuan Pharmaceutical Hldgs (460 HK)</a>, whose share price was up over 318% since the beginning of 2021 on the back of its medical beauty business, with market cap of HK$32.5 billion and P/E ratio of 57.17, which is pretty eye-catching. So could the medical beauty business revalue the Company? This insight mainly analyzed the business outlook and the concerns.

Since 2021, if you want to ask which sector in the healthcare industry has outstanding performance, the medical beauty sector is definitely the one. Looking at the leading companies in this sector, the market cap and P/E ratio of Bloomage Biotechnology Corporation-A (688363 CH) by the end of May 28, 2021 were RMB121 billion and 175, respectively. For Imeik Technology Development (300896 CH), they were RMB142 billion and 250, respectively. Both were at high end and very expensive. Here is another company, Sihuan Pharmaceutical Hldgs (460 HK), whose share price was up over 318% since the beginning of 2021 on the back of its medical beauty business, with market cap of HK$32.5 billion and P/E ratio of 57.17, which is pretty eye-catching. So could the medical beauty business revalue the Company? This insight mainly analyzed the business outlook and the concerns.

Sihuan Pharmaceutical (460.HK) - Optimistic in the Short Term but Conservative in the Long Term

<a href="https://www.smartkarma.com/entities/sihuan-pharmaceutical-hldgs" target="_blank" data-smartkarma-citation="entities:33:1" rel="noopener">Sihuan Pharmaceutical Hldgs (460 HK)</a> is one of the largest suppliers of cardio-cerebral vascular (“CCV”) prescription drugs in China. The Company is currently conducting more than 110 pharmaceutical research projects and over 300 patents on innovative drugs have been granted. The current pipeline covers key therapeutic areas including diabetes, oncology, anti-infectives, non-alcoholic steatohepatitis and so on. From January 19th to January 29th, Sihuan's share price rose about 110% in ten days, and the highest price ever reached HK$2.32. The question is, what happened to this Company that cause its share price to increase sharply?

Sihuan Pharmaceutical Hldgs (460 HK) is one of the largest suppliers of cardio-cerebral vascular (“CCV”) prescription drugs in China. The Company is currently conducting more than 110 pharmaceutical research projects and over 300 patents on innovative drugs have been granted. The current pipeline covers key therapeutic areas including diabetes, oncology, anti-infectives, non-alcoholic steatohepatitis and so on. From January 19th to January 29th, Sihuan's share price rose about 110% in ten days, and the highest price ever reached HK$2.32. The question is, what happened to this Company that cause its share price to increase sharply?

Sihuan Pharmaceutical (460 HK) - The Logic Behind the Rally of the Stock Price

China

Sihuan Pharmaceutical is a pharmaceutical and medical aesthetic company engaged in the research, development, manufacturing, and sale of products. It offers drugs across therapeutic areas such as oncology, metabolism, diabetes, and cardiovascular diseases, alongside medical aesthetic solutions. The company was founded in 2001 and is headquartered in Wan Chai, Hong Kong.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sihuan Pharmaceutical (460 HK)

Hong Kong Buybacks: China Gas, Hopson, Sihuan

We highlight in the past week the top 3 companies that repurchased the most shares from the market were China Gas (384 HK), Hopson (754 HK), Sihuan...

Ke Yan, CFA, FRM

Hong Kong Buybacks: Xiaomi, China Gas, Sihuan

We highlight the top 3 companies that repurchased the most shares from the market were Xiaomi (1810 HK), China Gas Holdings Limited (384 HK),...

Ke Yan, CFA, FRM